Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients

CD30-Positive Diffuse Large B-Cell Lymphoma Clinical Trial

Official title:
A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas

Status Completed

Clinical Trial Summary

This is a Phase I/II multicenter single arm non-randomized open label study of the investigational drug, brentuximab vedotin, given in combination with routine chemotherapy (rituximab, cyclophosphamide, doxorubicin and prednisone) every 3 weeks for a total of 6 cycles.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

CD30 Positive Primary Mediastinal Large B-cell Lymphoma
CD30-Positive Diffuse Large B-Cell Lymphoma
CD30-Positive Gray Zone Lymphoma
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse

Clinical Trial Details

NCT number	NCT01994850
Study type	Interventional
Source	Abramson Cancer Center of the University of Pennsylvania
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	November 2013
Completion date	January 2019

View Details

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT06176690` - Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas	Phase 1
	Not yet recruiting	`NCT05544968` - CD30biAb-AATC for CD30+ Malignancies	Phase 1/Phase 2